474 related articles for article (PubMed ID: 15271322)
1. The role of retroperitoneal lymph node dissection in the management of testicular cancer.
Stephenson AJ; Sheinfeld J
Urol Oncol; 2004; 22(3):225-33; discussion 234-5. PubMed ID: 15271322
[TBL] [Abstract][Full Text] [Related]
2. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update.
Yoon GH; Stein JP; Skinner DG
Urol Oncol; 2005; 23(3):168-77. PubMed ID: 15907716
[TBL] [Abstract][Full Text] [Related]
4. Surgery for testicular cancer: indication, results and technical aspects.
Khouni H; Ghozzi S; Ramzi K; Smaali CH; Majed H; Ben Rais N
Tunis Med; 2005 Dec; 83 Suppl 12():78-83. PubMed ID: 16430075
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.
Steiner H; Peschel R; Janetschek G; Höltl L; Berger AP; Bartsch G; Hobisch A
Urology; 2004 Mar; 63(3):550-5. PubMed ID: 15028456
[TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
8. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.
Heidenreich A; Ohlmann C; Hegele A; Beyer J
Eur Urol; 2005 Jan; 47(1):64-71. PubMed ID: 15582251
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
12. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
13. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
14. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
15. Retroperitoneal lymph node dissection in testicular cancer.
Jacobsen NE; Foster RS; Donohue JP
Surg Oncol Clin N Am; 2007 Jan; 16(1):199-220. PubMed ID: 17336244
[TBL] [Abstract][Full Text] [Related]
16. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
[TBL] [Abstract][Full Text] [Related]
17. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
Okamura K; Yuba H; Nishimura T; Mizutani K; Takashi M; Gotoh M; Ono Y; Ohshima S
Hinyokika Kiyo; 1999 Feb; 45(2):95-101. PubMed ID: 10212781
[TBL] [Abstract][Full Text] [Related]
19. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
